Advances in™ Diagnosis, Multidisciplinary Management, and Optimal Treatment of Amyotrophic Lateral Sclerosis

Released On
February 25, 2021

Expires On
February 25, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Neurology

Topic(s)
Parkinson's & Movement Disorders

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward neurologists, internists, and other health care professionals involved in the treatment of patients with amyotrophic lateral sclerosis (ALS), such as primary care providers, nurse practitioners, and physician assistants.

Program Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the management of patients with amyotrophic lateral sclerosis (ALS). It provides an overview of the complex disease etiology and pathophysiology of ALS, discusses the clinical presentation and diagnostic evaluation in this setting, emphasizes the importance of multidisciplinary care, and evaluates the efficacy and safety of therapies recommended for symptom control and of agents that may modify the disease course of ALS. This activity is presented in a multimedia format that includes a series of video interviews with a clinical expert integrated into text-based elements and an interactive clinical case.

Learning Objectives

Upon completion of this activity, you should be better able to:

  • Analyze the underlying pathophysiology of ALS and the barriers to accurate and early diagnosis
  • Utilize interdisciplinary strategies to manage the systemic burden for patients with ALS
  • Identify challenges and opportunities in using shared decision-making and supporting patient adherence
  • Discuss the efficacy and safety of disease-targeting and supportive therapies for patients with ALS

Faculty

Jinsy A. Andrews, MD, MSC

Jinsy A. Andrews, MD, MSC

Director of Neuromuscular Clinical Trials
Columbia University Irving Medical Center
Associate Professor of Neurology
Columbia University Irving Medical Center
New York, NY

Accreditation Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Jinsy A. Andrews, MD, MSC

  • Grant Research Support: Alexion, Biogen, Alexion, NIH, Healey Foundation, National Institutes of Health
  • Consultant: AveXis (now Novartis Gene Therapies), AL-S Pharma, Biogen, Cytokinetics, Denali, Wave Life Sciences

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and postactivity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.